Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c

Ultragenyx Pharma (RARE) Has Multiple Catalysts in 2015 - Jefferies

March 26, 2015 8:36 AM EDT

Jefferies analyst Ryan Martins reiterated a Buy rating and $74 price target on Ultragenyx Pharma (NASDAQ: RARE) noting multiple catalysts in 2015.

Martins commented, "All of RARE's clinical programs are on track, with either phase 2 data or initiation of pivotal trials planned in 2015. Key updates included... More

Jefferies Weighs In on Ultragenyx Pharma (RARE) Related to SIMD Abstracts

March 25, 2015 7:34 AM EDT

Jefferies analyst Ryan Martins provided his take on SIMD abstracts relevant to Ultragenyx Pharma (NASDAQ: RARE). The firm reiterated a Buy rating and $74 price target.

Martins commented, "RARE will present 12 month data from the eIND patient on rhGUS, where we expect... More